The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
BACKGROUND:Miltefosine (MF) is the only oral drug available for treatment of visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL). Although the drug is effective and well tolerated in treatment of VL, the efficacy and safety of MF for longer treatment durations (>28 days) in...
Main Authors: | Joyce Pijpers, Margriet L den Boer, Dirk R Essink, Koert Ritmeijer |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-02-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC6386412?pdf=render |
Similar Items
-
Kala-azar and Post–Kala-azar Dermal Leishmaniasis, Assam, India
by: Abdul Mabood Khan, et al.
Published: (2014-03-01) -
Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis
by: Krishna Pandey, et al.
Published: (2020-12-01) -
Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
by: V Ramesh, et al.
Published: (2015-01-01) -
Availability of miltefosine for the treatment of kala-azar in India
by: Shyam Sundar, et al.
Published: (2005-05-01) -
Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
by: Eduard E Zijlstra, et al.
Published: (2017-11-01)